Treatment planning in PRRT based on simulated PET data and a PBPK model: Behandlungsplanung in der PRRT basierend auf simulierten PET-Daten und einem PBPK-Modell

Deni Hardiansyah, Wei Guo, Ali Asgar Attarwala, Peter Kletting, Felix M. Mottaghy, Gerhard Glatting*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

Aim: To investigate the accuracy of treatment planning in peptide-receptor radionuclide therapy (PRRT) based on simulated PET data (using a PET noise model) and a physiologically based pharmacokinetic (PBPK) model. Methods: The parameters of a PBPK model were fitted to the biokinetic data of 15 patients. True mathematical phantoms of patients (MPPs) were the PBPK model with the fitted parameters. PET measurements after bolus injection of 150 MBq Ga-68-DOTATATE were simulated for the true MPPs. PET noise with typical noise levels was added to the data (i.e. c=0.3 [low], 3, 30 and 300 [high]). Organ activity data in the kidneys, tumour, liver and spleen were simulated at 0.5, 1 and 4 h p.i. PBPK model parameters were fitted to the simulated noisy PET data to derive the PET-predicted MPPs. Therapy was simulated assuming an infusion of 3.3 GBq of Y-90-DOTATATE over 30 min. Time-integrated activity coefficients (TIACs) of simulated therapy in tumour, kidneys, liver, spleen and remainder were calculated from both, true MPPs (true TIACs) and predicted MPPs (predicted TIACs). Variability v between true TIACs and predicted TIACs were calculated and analysed. Variability

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalNuklearmedizin
Volume56
Issue number1
DOIs
Publication statusPublished - 2017

Keywords

  • PBPK Model
  • PRRT
  • PET
  • PET noise model
  • RECEPTOR RADIONUCLIDE THERAPY
  • PHARMACOKINETIC MODEL
  • NEUROENDOCRINE TUMORS
  • ANTI-CD45 ANTIBODY
  • GA-68-DOTATATE PET/CT
  • GRAPHICAL ANALYSIS
  • RADIOIMMUNOTHERAPY
  • DOSIMETRY
  • SOFTWARE
  • BIODISTRIBUTION

Cite this